Industry News
Quick Verdict
WHOOP just made two moves that matter beyond its own ecosystem. On August 18 it opened Advanced Labs, its clinician-reviewed blood testing program, to everyone: no WHOOP band, no membership, panels starting around $150, with draws at roughly 2,000 Quest Diagnostics locations. And it added Galleri, GRAIL's multi-cancer early detection blood test, for $799 a year, delivered with results and follow-up inside the WHOOP app.
The catch is not the price. It is the numbers behind the screening. Galleri is a real, studied test with genuine strengths, especially for aggressive cancers that have no other screening at all. It also misses most early-stage cancers, returns a meaningful share of alarms that no follow-up can confirm, and is not FDA approved. Whether it belongs in your health stack depends on your age, your risk, and how you will handle an ambiguous result. This article gives you the actual numbers so that decision is yours.
What WHOOP Announced
Two changes landed together. First, Advanced Labs no longer requires a WHOOP membership or a wearable. Anyone can book a blood draw through the WHOOP app, get panels covering cardiovascular, metabolic, hormonal, and inflammatory markers from about $150, and receive clinician-reviewed results with recommendations. Licensed providers order the tests and review the reports.
Second, the lineup now includes Galleri, GRAIL's blood test that screens for a cancer signal across more than 50 cancer types from a single draw, and predicts where in the body a detected signal likely originated. Through WHOOP it costs $799 as a once-a-year test, below the roughly $949 GRAIL has charged directly. It is intended for adults 50 and older, and is not for people under 22, currently pregnant, or in active cancer treatment.
Strategically, this is WHOOP finishing a pivot it started when it launched Advanced Labs with Quest in 2025: from a recovery band for athletes into a general health platform where the wearable is optional and the lab work is the product. A cancer screen in the same app as your sleep and strain data is the clearest statement yet of that ambition.
What Galleri Actually Is
Galleri looks for fragments of DNA that tumors shed into the bloodstream, and uses the chemical patterns on those fragments to flag a possible cancer signal and estimate its origin. It is a screening test, not a diagnosis: a positive result means follow-up imaging and workup with a clinician, and a negative result does not rule cancer out.
Its appeal is real. Standard screening exists for only a handful of cancers, and many of the deadliest, including pancreatic and ovarian, are usually found late precisely because nothing screens for them. A blood test that can sometimes surface those cancers earlier is a legitimately new capability, and that is why it has drawn both serious research and serious hype.
The Numbers the Marketing Does Not Lead With
The most useful recent data comes from PATHFINDER 2, a study of about 35,900 adults in a real screening population. The headline results cut both ways:
| Measure | Result | What it means |
|---|---|---|
| Overall cancer detection | ~40% | Most cancers present in the study population were not flagged |
| High-mortality cancers | ~74% detected | Strongest where screening matters most and alternatives are fewest |
| Early-stage sensitivity | Weak (under 20% for stage I in earlier CCGA data) | The test is much better at finding advanced cancer than early cancer |
| False positive rate | ~0.4% | Very few cancer-free people get flagged |
| Unconfirmed positives | ~38% of signals | A meaningful share of alarms lead to workups that find nothing |
Read those together and the honest summary is: Galleri rarely cries wolf, catches a real share of dangerous cancers that nothing else screens for, and misses most cancers at the stage where catching them changes outcomes the most. A negative Galleri result is weak evidence of anything. It does not replace colonoscopies, mammograms, or any standard screening, and GRAIL itself positions it as an addition, not a substitute.
Two more facts belong in the decision. Galleri is sold as a laboratory-developed test and has not been FDA approved; an FDA advisory panel is scheduled to review multi-cancer early detection testing on September 23, 2026, which could shape how these tests are regulated. And a positive signal starts a diagnostic odyssey of scans and possibly biopsies that is stressful and not free, which is why the unconfirmed-positive rate matters as much as the false-positive rate.
Who Should Actually Consider It
The strongest case: you are over 50, especially with elevated risk (family history, smoking history), you are already up to date on standard screenings, you can absorb $799 a year, and you have thought through how you would handle a positive signal that imaging cannot confirm. For that person, Galleri buys a real, if partial, look at cancers nothing else checks.
The weak case: you are under 50 and healthy, in which case you are outside the intended population entirely, or you would treat a negative result as reassurance. It is not designed to give you that, and $799 a year buys a lot of the boring screening and daily habits that actually move mortality risk.
Credit where due: WHOOP's own materials state the eligibility limits and route every result through licensed clinicians, which is the responsible version of this product. The risk is in how people read it, not just how it is sold.
What It Means for the Wearable Wars
Advanced Labs without a membership is arguably the bigger business story. WHOOP spent a decade as the strictest subscription company in wearables, and it just built a front door that requires no subscription and no hardware. Oura added telehealth and health-record imports with Ring 5; Function Health raised $450M on lab testing; now WHOOP sells lab work to people who have never worn a WHOOP. Every serious player is converging on the same thesis: the money and the moat are in owning your health data pipeline, not the gadget.
If you are evaluating WHOOP itself, our guides to whether WHOOP is still worth it in 2026 and WHOOP 5 vs WHOOP MG cover the wearable side, and the best no-subscription alternatives covers the exits.
Where Vora Fits
Vora sits on the same conviction with a different architecture: your labs belong next to your daily behavior, not in a separate app per vendor. Vora imports bloodwork and tracks biomarkers over time alongside the sleep, training, nutrition, and recovery data it already reads from whatever you wear, so a lipid panel or an inflammatory marker lands in the same picture as the habits that move it.
A screening like Galleri, if you choose it, produces exactly the kind of result that should not live alone in a silo: it is context that belongs with your history, your other labs, and your clinician. Whoever you buy your blood work from, keep your copies, and keep them somewhere that outlives any one company's app. That principle, not any single test, is what proactive health actually runs on.